Previous Close | 28.28 |
Open | 28.28 |
Bid | 29.40 x 1100 |
Ask | 30.14 x 1100 |
Day's Range | 27.21 - 28.36 |
52 Week Range | 20.67 - 42.48 |
Volume | |
Avg. Volume | 1,662,316 |
Market Cap | 3.486B |
Beta (5Y Monthly) | 0.72 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.77 |
Earnings Date | Apr 30, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 55.38 |
Subscribe to Yahoo Finance Plus to view Fair Value for ARWR
After closing out 2023 with a 15.1% gain, the Russell 2000 looks even better this year in the new year. In fact, since Jan. 2, the index is up about 4% year to date, and could push even higher, taking some of the most undervalued Russell 2000 stocks along for the ride. According to Goldman Sachs, the Russell 2000 Index could return about 9% in the first six months of the year, and about 15% in the next 12 months. All thanks to low valuations, and an improving economic outlook. As noted by Invest
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CFO Kenneth Myszkowski sold 40,000 shares of the company's stock on March 6, 2024, according to a recent SEC filing.
PASADENA, Calif., March 08, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a double-blinded, placebo-controlled, dose-escalating study (NCT06138743) to evaluate single and multiple ascending doses of ARO-DM1, the company’s investigational RNA interference (RNAi) therapeutic, in up to 48 subjects with type 1 myotonic dystrophy (DM1). DM1 is the most common adult-onset muscular dystrophy.